Tirzepatide, a recently popular weight-loss drug, is advised for individuals with certain cases of type 2 diabetes and obesity, according to Zuellig Pharma, a pharmaceuticalTirzepatide, a recently popular weight-loss drug, is advised for individuals with certain cases of type 2 diabetes and obesity, according to Zuellig Pharma, a pharmaceutical

Weight-loss drug tirzepatide advised only for adults with diabetes and obesity according to Zuellig Pharma

2026/02/10 11:38
2 min read
For feedback or concerns regarding this content, please contact us at [email protected]

Tirzepatide, a recently popular weight-loss drug, is advised for individuals with certain cases of type 2 diabetes and obesity, according to Zuellig Pharma, a pharmaceutical company.

The drug, fondly known as “Tirz,” recently gained popularity due to its dual-action mechanism, which can help regulate both blood sugar and body weight.

In an email interview, Zuellig Pharma said that tirzepatide (brand name: Mounjaro), for instance, targets both GIP and GLP-1—hormones that help regulate blood sugar after meals—to support blood sugar control and weight management.

“By targeting both GIP and GLP-1, the drug works on the brain and metabolism at the same time,” said David Cummings, a professor at the University of Washington.

“This doesn’t just lower blood sugar; it resets the body’s weight set-point, offering clinical results that were previously difficult to achieve through traditional means,” Mr. Cummings added during a forum led by Zuellig Pharma on Jan. 27.

The brand Mounjaro KwikPen, exclusively and authorized for distribution by Zuellig Pharma, is the only tirzepatide brand approved in the country by the Food and Drug Administration as of this writing.

Meanwhile, Dr. Gyneth Lourdes Bibera, Zuellig Pharma’s medical director, said that tirzepatide is advised for adults whose type 2 diabetes is not sufficiently controlled with diet and exercise.

It is also recommended for adults with obesity (BMI ≥ 30) or overweight (BMI 27–29.9) who have at least one weight-related health condition, such as hypertension, cardiovascular disease, or dyslipidemia, among others.

Tirzepatide can be prescribed alone when metformin is considered inappropriate due to intolerance or contraindications, or in combination with other diabetes medications for better blood sugar control.

“It is also indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance,” Ms. Bibera added, noting that this applies to adults meeting the criteria above.

The World Health Organization (WHO) supports the use of GLP-1 therapies, including tirzepatide, for adults with obesity and type 2 diabetes as part of a comprehensive treatment plan.

WHO also noted that these medications should be used alongside lifestyle changes such as diet and exercise, while emphasizing the need for monitoring, long-term safety evaluation, and equitable access.

The Mounjaro KwikPen is available at leading drugstores nationwide, but only with a doctor’s prescription. — Edg Adrian A. Eva

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

Hyperliquid Policy Center’s Concerns Over CLARITY Act– Urges Fixes To Protect DeFi Developers

Hyperliquid Policy Center’s Concerns Over CLARITY Act– Urges Fixes To Protect DeFi Developers

A fresh round of disagreement over the CLARITY Act has revealed ongoing concerns originating from the Hyperliquid Policy Center (HPC), as lawmakers prepare for
Share
Bitcoinist2026/03/28 08:01
How Will XRP Price React After the FOMC Meeting Today?

How Will XRP Price React After the FOMC Meeting Today?

The post How Will XRP Price React After the FOMC Meeting Today? appeared first on Coinpedia Fintech News The U.S. Federal Reserve is set to announce its latest interest rate decision today, and the outcome could have a direct impact on the crypto market, including XRP. Fed Expected to Cut Rates The current Fed funds rate is at 4.5%. Markets are widely expecting a 25 basis point cut, bringing the rate down to …
Share
CoinPedia2025/09/17 23:58
USDH Power Struggle Ignites Stablecoin “Bidding Wars” Across DeFi: Bloomberg

USDH Power Struggle Ignites Stablecoin “Bidding Wars” Across DeFi: Bloomberg

A heated contest for control over a new dollar-pegged token has set the stage for what analysts say could define the next phase of the stablecoin industry. According to Bloomberg, a bidding war unfolded on Hyperliquid, one of crypto’s fastest-growing trading platforms, with the prize being the right to issue USDH, its native stablecoin. The competition drew some of the sector’s most prominent names, including Paxos, Sky, and Ethena, who later withdrew their bid, alongside the lesser-known Native Markets, a startup backed by Stripe stablecoin subsidiary Bridge. Hyperliquid Stablecoin Race Shows Branding and Partnerships Matter as Much as Tech Over the weekend, Hyperliquid’s validators, the contributors who secure the network and vote on key decisions, awarded the USDH contract to Native Markets over the weekend. Despite its relatively new status, the firm’s connection with Stripe helped it outpace more established rivals. Stablecoins underpin decentralized finance by providing a dollar-backed medium for collateral, settlement, and payments across applications. What began as a grassroots, community-led sector has evolved into a battleground for institutions and payment companies seeking revenue from interest on reserves. Circle, for example, shares proceeds from its USDC with Coinbase under a partnership designed to stabilize earnings during market swings. The Hyperliquid contest offered a rare glimpse into just how intense competition has become. Paxos pledged to take no revenue until USDH surpassed $1 billion in circulation. Agora offered to share 100% of net revenue with Hyperliquid, while Ethena put forward 95%. All were outbid by Native Markets, whose ties to Stripe’s $1.1 billion acquisition of Bridge and subsequent rollout of the Tempo blockchain positioned it as a strong contender. “Every stablecoin issuer is extremely desperate for supply,” said Zaheer Ebtikar, co-founder of Split Capital. “They are willing to publicly announce how much they are willing to offer. It just shows it’s a very tough business for stablecoin issuers.” While USDC remains dominant on Hyperliquid with more than $5.6 billion in deposits, the arrival of USDH could shift flows and revenue dynamics. Paxos co-founder Bhau Kotecha said the firm sees the exchange’s growth as an important opportunity, while Agora’s co-founder Nick van Eck warned that awarding the contract to a vertically integrated issuer risked undermining decentralization. Regulatory positioning also factored into the debate. Paxos operates under a New York trust charter and is seeking a federal license, while Bridge holds money transmitter approvals in 30 states. Native Markets, in a blog post, cited regulatory flexibility and deployment speed as reasons for its selection. Hyperliquid said the strong engagement from its community validated the process. Circle CEO Jeremy Allaire dismissed concerns over USDC’s status, noting on X that competition benefits the ecosystem. Analysts suggested that fears of centralization may be exaggerated, noting that Hyperliquid is likely to remain neutral and support multiple stablecoins. Still, the contest over USDH highlighted a new reality for stablecoins: branding, partnerships, and business strategy are becoming as decisive as technology. Native Markets Secures USDH Stablecoin Mandate on Hyperliquid Hyperliquid has concluded its governance vote for the USDH stablecoin, awarding the mandate to Native Markets after a closely watched process that drew weeks of community debate and rival proposals. USDH, described by Hyperliquid as a “Hyperliquid-first, compliant, and natively minted” dollar-backed token, is intended to reduce the platform’s dependence on USDC and strengthen its spot markets. Validators on the decentralized exchange voted in favor of Native Markets, a relatively new player backed by Stripe’s Bridge subsidiary, over established contenders including Paxos and Ethena. The outcome followed a string of proposals offering aggressive revenue-sharing terms to win validator support, underscoring the scale of incentives attached to controlling USDH. Hyperliquid’s exchange has become a critical hub for stablecoin liquidity, with $5.7 billion in USDC, around 8% of its total supply, currently held on the network. At prevailing treasury yields, that translates to an estimated $200 million to $220 million in annual revenue for Circle, underlining why a native alternative could be transformative. Hyperliquid’s validators, who secure the network and vote on key decisions, selected Native Markets following an on-chain governance process that concluded September 15. Native Markets has laid out a phased rollout for USDH, beginning with capped minting and redemption trials before expanding into spot markets. Its reserves will be managed in cash and treasuries by BlackRock, with on-chain tokenization through Superstate and Bridge. Yield from those reserves will be split between Hyperliquid’s Assistance Fund and ecosystem development. The launch of USDH comes as Hyperliquid records record profits from perpetual futures trading, with $106 million in revenue in August alone, and prepares to slash spot trading fees by 80% to bolster liquidity. Analysts say the move positions Hyperliquid to capture more of the stablecoin economics internally, marking a significant step in its bid to rival the largest players in decentralized finance
Share
CryptoNews2025/09/18 00:48